FDA OKs First Gene Therapy for Hemophilia B
Share on Facebook Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved the first gene therapy for treating hemophilia B, a genetic bleeding disorder resulting from missing or insufficient levels of factor IX.
Tuesday, November 22, 2022 at 10:47 pm